Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127145281 | 12714528 | 1 | I | 20150522 | 20150804 | 20160905 | 20160905 | EXP | US-ROCHE-1617739 | ROCHE | 58.00 | YR | M | Y | 86.60000 | KG | 20160905 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127145281 | 12714528 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | INDUCTION (CYCLE=21 DAYS); ON DAY 1 OF CYCLES 1-4; (CYCLE 1) | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127145281 | 12714528 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | INDUCTION (CYCLE=21 DAYS); ON DAY 1 OF CYCLES 1-4?1307 MG | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127145281 | 12714528 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | INDUCTION (CYCLE=21 DAYS); ON DAY 1 OF CYCLES 1-4; (CYCLE 3)?DATE OF LAST DOSE ADMINISTERED: 05/JUN/ | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127145281 | 12714528 | 4 | SS | IPILIMUMAB | IPILIMUMAB | 1 | Intravenous (not otherwise specified) | INDUCTION (CYCLE=21 DAYS); ON DAY 1 OF CYCLES 1-4; (CYCLE 1)?DATE OF LAST DOSE ADMINISTERED: 05/JUN/ | U | 0 | 3 | MG/KG | |||||||
| 127145281 | 12714528 | 5 | SS | IPILIMUMAB | IPILIMUMAB | 1 | Intravenous (not otherwise specified) | INDUCTION (CYCLE=21 DAYS); ON DAY 1 OF CYCLES 1-4?261 MG | U | 0 | 3 | MG/KG | |||||||
| 127145281 | 12714528 | 6 | SS | IPILIMUMAB | IPILIMUMAB | 1 | Intravenous (not otherwise specified) | INDUCTION (CYCLE=21 DAYS); ON DAY 1 OF CYCLES 1-4; (CYCLE 3)?261 MG | U | 0 | 3 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127145281 | 12714528 | 1 | Malignant melanoma |
| 127145281 | 12714528 | 4 | Malignant melanoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127145281 | 12714528 | HO |
| 127145281 | 12714528 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127145281 | 12714528 | Headache | |
| 127145281 | 12714528 | Hypertension | |
| 127145281 | 12714528 | Hypophysitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127145281 | 12714528 | 1 | 20150424 | 0 | ||
| 127145281 | 12714528 | 2 | 20150515 | 0 | ||
| 127145281 | 12714528 | 3 | 20150605 | 0 | ||
| 127145281 | 12714528 | 4 | 20150424 | 0 | ||
| 127145281 | 12714528 | 5 | 20150515 | 0 | ||
| 127145281 | 12714528 | 6 | 20150605 | 0 |